高级检索
当前位置: 首页 > 详情页

Novel nomograms for predicting overall survival and cancer-specific survival in invasive lobular carcinoma of the breast

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Shanghai Jiao Tong Univ, Tongren Hosp, Dept Breast Surg, Sch Med, 1111 Xianxia Rd, Shanghai 200336, Peoples R China
出处:
ISSN:

关键词: Invasive lobular carcinoma SEER Nomogram Prognosis

摘要:
PurposeCurrently, the clinical diagnosis and treatment for invasive lobular carcinoma of the breast (ILC) often draw on the treatment approaches used for invasive ductal carcinoma (IDC), despite significant differences between the two. Studies evaluating the risk and prognosis of ILC are limited; thus, our goal was to construct a predictive model for the prognosis of ILC.MethodsClinical data of patients diagnosed with unilateral primary ILC from 2010 to 2015 were acquired from the SEER database. Independent prognostic factors affecting patients' overall survival (OS) and cancer-specific survival (CSS) were determined through univariate and multivariate analyses based on COX proportional hazards model and Fine-Gray competing risks model. Nomograms were constructed to forecast the 1-year, 3-year, and 5-year OS and CSS of the patients.ResultsA total of 6,616 patients with ILC were included, with 1,083 deaths, of which 541 were attributed to ILC, and 542 to other causes. The univariate and multivariate analyses indicated that age, N stage, stage, surgery, PR status, radiotherapy, and brain metastasis are independent risk factors for OS of ILC patients, while age, N stage, stage, surgery, PR status, and brain metastasis are independent risk factors for CSS of ILC patients. The C-index, area under the ROC curve, and calibration curve of the 1-, 3-, and 5-year OS and CSS prediction models confirmed that it had good predictive capability.ConclusionsThis study has developed subtype-specific predictive models for OS and CSS of patients with ILC, offering clinicians a regimen. Reference for assessing patient prognosis and formulating individualized treatment.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 4 区 医学
小类 | 4 区 内分泌学与代谢 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 内分泌学与代谢 4 区 肿瘤学
JCR分区:
出版当年[2023]版:
Q2 ONCOLOGY Q3 ENDOCRINOLOGY & METABOLISM
最新[2024]版:
Q2 ENDOCRINOLOGY & METABOLISM Q2 ONCOLOGY Q3 ENDOCRINOLOGY & METABOLISM

影响因子: 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者:
第一作者机构: [1]Shanghai Jiao Tong Univ, Tongren Hosp, Dept Breast Surg, Sch Med, 1111 Xianxia Rd, Shanghai 200336, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:28967 今日访问量:0 总访问量:1619 更新日期:2025-10-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)